Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LMK235 in medicine for inhibiting scar formation

A technology of drug action and drug, applied in the directions of drug delivery, drug combination, pharmaceutical formulation, etc., can solve the problems of inaccurate therapeutic target, limited clinical efficacy, high cytotoxicity, etc., to avoid unclear treatment mechanism and shallow treatment depth. , the effect of clear therapeutic targets

Inactive Publication Date: 2020-09-22
SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The limitations of the existing methods of preventing and treating pathological scars mainly include: 1. Surgical therapy, the treatment process is painful, the recurrence rate is high, and it cannot be applied to patients with large scars; 2. Compression therapy and silicone product treatment are not suitable for large The effect is better for patients with surface burns, but patients need to wear elastic compression devices for a long time, which seriously inconveniences their lives; 3. Radiation therapy, the therapeutic effect is limited, and often causes permanent radiation damage to the patient's whole body and local area; 4. Cryotherapy, only applicable 5. Glucocorticoid treatment can cause skin atrophy, depigmentation, telangiectasia, female menstrual disorders, and ulceration at the injection site or calcification and other complications; 6. Laser therapy, the clinical efficiency is low, and it is easy to induce new scars; 7. Antineoplastic drug therapy is highly toxic to local and systemic normal cells, and the clinical value is not yet clear; Limus, statins, tamoxifen and other drugs have limited clinical efficacy, and the therapeutic targets are not yet clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LMK235 in medicine for inhibiting scar formation
  • Application of LMK235 in medicine for inhibiting scar formation
  • Application of LMK235 in medicine for inhibiting scar formation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Use of LMK235 in drugs that inhibit scar formation.

[0032] 1. Experimental materials

[0033] 1.1 The preparation method of LMK235 solution is as follows:

[0034] LMK235 was purchased from Selleck (#7569), dissolved in normal saline, and prepared into solutions with LMK235 concentrations of 5ng / ml, 10ng / ml, 25ng / ml and 50ug / ml respectively.

[0035] 2. Experimental method

[0036] 2.1 Extraction and culture of human scar-derived fibroblasts

[0037] Take clinical specimens (human hypertrophic scar tissue, the patient has signed an informed consent form) soaked in Dispase II (2mg / ml, Life Technologies, ThermoFisher), overnight at 4°C, and peel off the epidermis. Mince the tissue under a sterile environment, soak it with 4mg / ml collagenase, digest it on a shaker at 37°C for 2-4 hours, filter the cell suspension with a filter, centrifuge at 1500rpm for 5min, remove the supernatant, and resuspend the cell pellet with the medium, inoculate to DMEM medium. Change the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of LMK235 in a medicine for inhibiting scar formation. Application of LMK235 as a medicine for treating hypertrophic scars is proposed for the first time. Injectionof LMK235 into the scars has obvious effects of inhibiting formation of the hypertrophic scars. The related medicine is clear in therapeutic target, and the defects that therapeutic mechanisms are unknown, the efficiency is low, side effects are easily caused, and the like are overcome; a series of side effects which can be brought by hormones are avoided; the probability of damage to normal humancells is avoided; the defect of shallow treatment depth is overcome, and the probability of induced formation of new scars is avoided; and large-area pathological scars can be treated, so that the defect of a small treatment scope is overcome.

Description

technical field [0001] The present invention relates to the field of application of LMK235, in particular to the application of LMK235 in drugs for inhibiting scar formation. Background technique [0002] Hypertrophic scar is a fibrotic skin disease, which is a fibrous metabolic disease of the skin dermis characterized by uncontrolled proliferation of fibroblasts and excessive production and deposition of a large amount of extracellular matrix such as collagen. It affects the physical and mental health of millions of people worldwide. Usually secondary to trauma, burns, and surgery. It has been reported that the incidence rate in patients after conventional surgery is 36-64%, and the incidence rate in patients with deep burns can be as high as 91%. Hypertrophic scars not only affect the appearance of patients, but also lead to varying degrees of dysfunction and seriously reduce the quality of life of patients. [0003] A large amount of clinical evidence shows that hypert...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/166A61P17/02
CPCA61K9/0014A61K9/0019A61K31/166A61P17/02
Inventor 高雅张艺凡侯家康李青峰
Owner SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products